ANACETRAPIB

Anacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

The large morbidity and mortality trial with anacetrapib, known as REVEAL and run by researchers at the University of Oxford, is currently ongoing, and full results are expected in 2017.

There is not enough information about the side effects of this drug. However, since it contains inactive ingredients, allergic reaction may be triggered.

Precautions

The use of this drug has not approved yet due to insufficient data. There is an on-going research about this drug.

 

Interactions

Research is still on-going there is no full result about it yet.

Data hasn’t proved yet that increasing HDL (or too much intake of this drug) is bad for someone’s health. Research about this is still on going.

Related Articles

ORPHENADRINE + PARACETAMOL

Orphenadrine, a tertiary amine antimuscarinic, is an indirect skeletal muscle stimulator with central atropine-like actions. It also has some local [...]

VACCINE, INFLUENZA

Influenza vaccine boosts protection against the influenza virus by stimulating the development of particular antibodies. Use this medication precisely as [...]

VACCINE, HUMAN PAPILLOMAVIRUS TYPES 16 AND 18 (RECOMBINANT)

Human Papillomavirus (HPV) bivalent vaccine is a non-infectious adjuvanted vaccination created by recombinant technology. It includes non-active virus-like particles (VLP) [...]